Jotbody

What Jotbody does

Jotbody is a Hong Kong-based biotechnology company founded in 2020 and operating from Hong Kong Science Park, specializing in single-domain antibody (nanobody) discovery and extracellular vesicle (EV) engineering. The company organizes its commercial activity around two parallel platforms — Nanobody World for antibody discovery, humanization, bioconjugation, and AI-driven optimization, and EV World for EV isolation, purification, characterization, omics analysis, and functionalization. Its proprietary reagent catalog includes the EVCraft isolation kit and the EVFect engineering/loading kit, which together target the upstream research workflow that feeds into its service contracts. The headcount disclosed is 1-10 employees.

The business model is B2B services plus catalog reagent sales to the global life-sciences research community, spanning academic groups, biotech developers, and pharmaceutical partners. Named disclosed customers include InnoRNA, SPH Biotherapeutics, Exopharm, and Université Grenoble Alpes, and the company states a customer footprint in 30+ countries supported by 200+ publications and 5,000+ citations referencing its technologies. The company has extended its service surface into contract development and manufacturing (CDMO), positioning it to capture downstream economics on nanobody and EV-based therapeutic programs that originate in its discovery work. No funding rounds, patents, or partnership transactions are disclosed.

Jotbody's strategic posture is that of a vertically integrated niche CRO and reagent vendor, attempting to consolidate a relatively specialized intersection of antibody engineering and EV biology under two branded platforms. Geographic reach and citation footprint suggest inbound demand generation from the academic community, while the CDMO and reagent-kit moves indicate a deliberate push up the value chain from fee-for-service discovery toward higher-value manufacturing and consumables revenue.

Name

Jotbody

Legal name

Jotbody (HK) Ltd

Website

https://jotbody.net

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Jotbody is a Hong Kong-based biotech founded in 2020 that provides nanobody discovery, extracellular vesicle engineering, and proprietary reagent kits (EVCraft, EVFect) to academic and biotech customers across 30+ countries, with CDMO services for therapeutic programs.

Ownership category

akta.pro rank

Product category

Biotechnology Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAAAIAB

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAAAG

Nanobodies & Alternative Antibody Scaffolds

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

SECONDARYHLAAAAAJ

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

SECONDARYHLAGAIAI

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

Keywords

• Nanobody discovery services
• Extracellular vesicle services
• Antibody research reagents
• Contract research services
• Biotechnology services

Headquarters

HQ city

New Territories

HQ country

Hong Kong SAR China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Nanobody Discovery Services: Contract research services for nanobody discovery including immunized and naive library screening, humanization, and bioconjugation.
2. Extracellular Vesicle Services: EV-related services including isolation, purification, characterization, omics, functionalization, and CDMO solutions.
3. Research Reagents: Sale of nanobody-based and extracellular vesicle-based research reagents through e-commerce platform.
4. Supporting Services: Additional services including sequencing, large-scale protein production, ELISA kits development, antibody validation, and in vitro/in vivo antibody drug evaluation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Jotbody provides contract research services and research reagents focused on two technology platforms: nanobodies (single-domain antibodies) and extracellular vesicles (EVs). The Nanobody World platform offers end-to-end discovery, humanization, bioconjugation, multispecific development, AI optimization, and Fc-fusion services, while the EV World platform provides isolation, purification, characterization, omics, functionalization, and CDMO solutions. The company also sells proprietary reagent kits including the EVCraft Surface Modification Kit and EVFect Transfection Kit through its online shop.

Product overview

Jotbody is a life science services and reagents company offering two integrated platforms: the Nanobody World platform providing discovery, humanization, bioconjugation, multispecific development, AI-powered optimization, and Fc-fusion services; and the Extracellular Vesicle (EV) World platform offering isolation, purification, characterization, omics analysis, functionalization, and CDMO solutions. The company also provides supplementary services including sequencing, large-scale protein production, ELISA kit development, and antibody validation. Jotbody sells research reagents under the EVCraft and EVFect brands including the Surface Modification Kit and Transfection Kit for EV manipulation.

Differentiator

Problem solved

Functional benefit

Brands

• EVCraft Surface Modification Kit: A novel kit utilizing cutting-edge bioconjugation techniques to facilitate efficient functionalization of EV surfaces
• EVFect Transfection Kit

Products and services

• Nanobody Discovery Full-service nanobody discovery from immunization to lead identification, providing custom nanobody generation for research and therapeutic applications.
• Humanization Conversion of animal-derived nanobodies into human-like sequences for therapeutic development.
• Bioconjugation Chemical conjugation services to attach labels, drugs, or other molecules to nanobodies for targeted applications.
• Multispecific Nanobody Development Development of multi-specific nanobody constructs that target multiple antigens simultaneously.
• AI Optimization

Quantifiable outcome

• 30+ countries served globally
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• AbCellera Biologics: AbCellera is a large, publicly-traded antibody discovery platform with leading capabilities in single-domain antibodies and partnerships with major pharma. It is a broader incumbent in the antibody discovery space where Jotbody competes.
• Lonza Group: Lonza is a global CDMO offering services including EV/exosome manufacturing and cell/gene therapy development. It is a broad incumbent whose EV CDMO solutions directly overlap with Jotbody's EV World CDMO offering.
• Bio-Techne: Bio-Techne is a large life science tools company offering antibodies, ELISA kits, proteins, and EV research reagents. It is a broad incumbent with overlapping product categories to Jotbody's reagent and assay services.
• argenx: argenx is a commercial-stage biotech that pioneered VHH/nanobody-based therapeutics (VYVGART) and is a benchmark for the nanobody therapeutics category. While therapeutic-focused rather than services, it validates the market and raises the competitive ceiling for nanobody CROs.
• Proteintech Group: Proteintech is a major antibody and reagent manufacturer with a broad catalog including nanobody-based products (Chromotek). It is a broad incumbent competing with Jotbody's e-commerce reagent business.

Direct peers

• Creative Biolabs: Creative Biolabs is a CRO offering custom antibody and nanobody discovery, humanization, and bioconjugation services. It is a direct competitor to Jotbody's Nanobody World platform with a comparable service catalog and global customer base.
• Izon Science: Izon Science manufactures instruments and consumables for extracellular vesicle isolation, purification, and characterization (qNano). It is a direct competitor in the EV research tools market that Jotbody serves.
• System Biosciences (SBI): SBI is a reagent company specializing in exosome/EV research tools including isolation kits, characterization reagents, and engineering services. It directly competes with Jotbody's EV World platform and reagent portfolio.
• Elasmogen: Elasmogen is a CRO specializing in soloMER (nanobody) discovery and development for therapeutic and diagnostic applications. It directly competes with Jotbody on nanobody discovery services and reagent sales.
• Vivlion GmbH: Vivlion offers proprietary 3H (Heavy-Humanized-Haploid) nanobody discovery platforms and custom screening services. It is a direct competitor in the contract nanobody discovery and engineering market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/jotbody
• Facebookfacebook.com/jotbodya
• LinkedInlinkedin.com/company/jotbody

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jotbody